BMS 189664
Latest Information Update: 18 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 18 Jan 2005 Discontinued - Clinical-Phase-Unknown for Thrombosis in USA (IV)
- 18 Jan 2005 Discontinued - Clinical-Phase-Unknown for Thrombosis in USA (PO)
- 22 Jun 1998 New profile